Sildenafil (Viagra) sensitizes prostate cancer cells to doxorubicin-mediated apoptosis through CD95

Anindita Das, David Durrant, Clint Mitchell, Paul Dent, Surinder Kumar Batra, Rakesh C. Kukreja

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We previously reported that Sildenafil enhances apoptosis and antitumor efficacy of doxorubicin (DOX) while attenuating its cardiotoxic effect in prostate cancer. In the present study, we investigated the mechanism by which sildenafil sensitizes DOX in killing of prostate cancer (PCa) cells, DU145. The death receptor Fas (APO-1 or CD95) induces apoptosis in many carcinoma cells, which is negatively regulated by anti-apoptotic molecules such as FLIP (Fas-associated death domain (FADD) interleukin-1-converting enzyme (FLICE)-like inhibitory protein). Co-treatment of PCa cells with sildenafil and DOX for 48 hours showed reduced expression of both long and short forms of FLIP (FLIP-L and -S) as compared to individual drug treatment. Over-expression of FLIP-s with an adenoviral vector attentuated the enhanced cellkilling effect of DOX and sildenafil. Colony formation assays also confirmed that FLIP-S over-expression inhibited the DOX and sildenafil-induced synergistic killing effect as compared to the cells infected with an empty vector. Moreover, siRNA knock-down of CD95 abolished the effect of sildenafil in enhancing DOX lethality in cells, but had no effect on cell killing after treatment with a single agent. Sildenafil co-treatment with DOX inhibited DOX-induced NF-κB activity by reducing phosphorylation of IγB and nuclear translocation of the p65 subunit, in addition to down regulation of FAP- 1 (Fas associated phosphatase-1, a known inhibitor of CD95-mediated apoptosis) expression. This data provides evidence that the CD95 is a key regulator of sildenafil and DOX mediated enhanced cell death in prostate cancer.

Original languageEnglish (US)
Pages (from-to)4399-4413
Number of pages15
JournalOncotarget
Volume7
Issue number4
DOIs
StatePublished - 2016

Fingerprint

Doxorubicin
Prostatic Neoplasms
Apoptosis
CASP8 and FADD-Like Apoptosis Regulating Protein
Sildenafil Citrate
Caspase 1
Death Domain Receptors
Phosphoric Monoester Hydrolases
Small Interfering RNA
Cell Death
Down-Regulation
Phosphorylation
Carcinoma
Pharmaceutical Preparations

Keywords

  • CD95
  • Doxorubicin
  • FLIP
  • PDE5
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Sildenafil (Viagra) sensitizes prostate cancer cells to doxorubicin-mediated apoptosis through CD95. / Das, Anindita; Durrant, David; Mitchell, Clint; Dent, Paul; Batra, Surinder Kumar; Kukreja, Rakesh C.

In: Oncotarget, Vol. 7, No. 4, 2016, p. 4399-4413.

Research output: Contribution to journalArticle

Das, Anindita ; Durrant, David ; Mitchell, Clint ; Dent, Paul ; Batra, Surinder Kumar ; Kukreja, Rakesh C. / Sildenafil (Viagra) sensitizes prostate cancer cells to doxorubicin-mediated apoptosis through CD95. In: Oncotarget. 2016 ; Vol. 7, No. 4. pp. 4399-4413.
@article{f8743caba30e4a7f86a356b1b77ca3b9,
title = "Sildenafil (Viagra) sensitizes prostate cancer cells to doxorubicin-mediated apoptosis through CD95",
abstract = "We previously reported that Sildenafil enhances apoptosis and antitumor efficacy of doxorubicin (DOX) while attenuating its cardiotoxic effect in prostate cancer. In the present study, we investigated the mechanism by which sildenafil sensitizes DOX in killing of prostate cancer (PCa) cells, DU145. The death receptor Fas (APO-1 or CD95) induces apoptosis in many carcinoma cells, which is negatively regulated by anti-apoptotic molecules such as FLIP (Fas-associated death domain (FADD) interleukin-1-converting enzyme (FLICE)-like inhibitory protein). Co-treatment of PCa cells with sildenafil and DOX for 48 hours showed reduced expression of both long and short forms of FLIP (FLIP-L and -S) as compared to individual drug treatment. Over-expression of FLIP-s with an adenoviral vector attentuated the enhanced cellkilling effect of DOX and sildenafil. Colony formation assays also confirmed that FLIP-S over-expression inhibited the DOX and sildenafil-induced synergistic killing effect as compared to the cells infected with an empty vector. Moreover, siRNA knock-down of CD95 abolished the effect of sildenafil in enhancing DOX lethality in cells, but had no effect on cell killing after treatment with a single agent. Sildenafil co-treatment with DOX inhibited DOX-induced NF-κB activity by reducing phosphorylation of IγB and nuclear translocation of the p65 subunit, in addition to down regulation of FAP- 1 (Fas associated phosphatase-1, a known inhibitor of CD95-mediated apoptosis) expression. This data provides evidence that the CD95 is a key regulator of sildenafil and DOX mediated enhanced cell death in prostate cancer.",
keywords = "CD95, Doxorubicin, FLIP, PDE5, Prostate cancer",
author = "Anindita Das and David Durrant and Clint Mitchell and Paul Dent and Batra, {Surinder Kumar} and Kukreja, {Rakesh C.}",
year = "2016",
doi = "10.18632/oncotarget.6749",
language = "English (US)",
volume = "7",
pages = "4399--4413",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "4",

}

TY - JOUR

T1 - Sildenafil (Viagra) sensitizes prostate cancer cells to doxorubicin-mediated apoptosis through CD95

AU - Das, Anindita

AU - Durrant, David

AU - Mitchell, Clint

AU - Dent, Paul

AU - Batra, Surinder Kumar

AU - Kukreja, Rakesh C.

PY - 2016

Y1 - 2016

N2 - We previously reported that Sildenafil enhances apoptosis and antitumor efficacy of doxorubicin (DOX) while attenuating its cardiotoxic effect in prostate cancer. In the present study, we investigated the mechanism by which sildenafil sensitizes DOX in killing of prostate cancer (PCa) cells, DU145. The death receptor Fas (APO-1 or CD95) induces apoptosis in many carcinoma cells, which is negatively regulated by anti-apoptotic molecules such as FLIP (Fas-associated death domain (FADD) interleukin-1-converting enzyme (FLICE)-like inhibitory protein). Co-treatment of PCa cells with sildenafil and DOX for 48 hours showed reduced expression of both long and short forms of FLIP (FLIP-L and -S) as compared to individual drug treatment. Over-expression of FLIP-s with an adenoviral vector attentuated the enhanced cellkilling effect of DOX and sildenafil. Colony formation assays also confirmed that FLIP-S over-expression inhibited the DOX and sildenafil-induced synergistic killing effect as compared to the cells infected with an empty vector. Moreover, siRNA knock-down of CD95 abolished the effect of sildenafil in enhancing DOX lethality in cells, but had no effect on cell killing after treatment with a single agent. Sildenafil co-treatment with DOX inhibited DOX-induced NF-κB activity by reducing phosphorylation of IγB and nuclear translocation of the p65 subunit, in addition to down regulation of FAP- 1 (Fas associated phosphatase-1, a known inhibitor of CD95-mediated apoptosis) expression. This data provides evidence that the CD95 is a key regulator of sildenafil and DOX mediated enhanced cell death in prostate cancer.

AB - We previously reported that Sildenafil enhances apoptosis and antitumor efficacy of doxorubicin (DOX) while attenuating its cardiotoxic effect in prostate cancer. In the present study, we investigated the mechanism by which sildenafil sensitizes DOX in killing of prostate cancer (PCa) cells, DU145. The death receptor Fas (APO-1 or CD95) induces apoptosis in many carcinoma cells, which is negatively regulated by anti-apoptotic molecules such as FLIP (Fas-associated death domain (FADD) interleukin-1-converting enzyme (FLICE)-like inhibitory protein). Co-treatment of PCa cells with sildenafil and DOX for 48 hours showed reduced expression of both long and short forms of FLIP (FLIP-L and -S) as compared to individual drug treatment. Over-expression of FLIP-s with an adenoviral vector attentuated the enhanced cellkilling effect of DOX and sildenafil. Colony formation assays also confirmed that FLIP-S over-expression inhibited the DOX and sildenafil-induced synergistic killing effect as compared to the cells infected with an empty vector. Moreover, siRNA knock-down of CD95 abolished the effect of sildenafil in enhancing DOX lethality in cells, but had no effect on cell killing after treatment with a single agent. Sildenafil co-treatment with DOX inhibited DOX-induced NF-κB activity by reducing phosphorylation of IγB and nuclear translocation of the p65 subunit, in addition to down regulation of FAP- 1 (Fas associated phosphatase-1, a known inhibitor of CD95-mediated apoptosis) expression. This data provides evidence that the CD95 is a key regulator of sildenafil and DOX mediated enhanced cell death in prostate cancer.

KW - CD95

KW - Doxorubicin

KW - FLIP

KW - PDE5

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84958020054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958020054&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.6749

DO - 10.18632/oncotarget.6749

M3 - Article

VL - 7

SP - 4399

EP - 4413

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 4

ER -